Lefflerová K, Lupínek Z, Widimský J, Lupínková Z, Uhlír O, Miklis P, Zeman K, Zicha J
Department of Cardiology, Postgraduate Medical and Pharmaceutical Institute, Prague, Czechoslovakia.
Cor Vasa. 1989;31(5):387-93.
The article presents the experience gained with a new betablocker- bopindolol-in the treatment of hypertension. Using a three-month double blind study conducted in 2 centres, the antihypertensive effect of bopindolol and metoprolol was compared in a total of 86 patients. The incidence of undesirable effects was determined, and biochemical parameters before and after therapy were followed up. Both drugs were equally effective in controlling blood pressure. In 70% of patients with mild and moderate hypertension, diastolic pressure values less than 95 mmHg were obtained in monotherapy with a betablocker. The incidence of undesirable effects was low, the drug was tolerated well. Biochemical parameters did not change within the three months of study.
本文介绍了一种新型β受体阻滞剂——波吲洛尔治疗高血压的经验。通过在两个中心进行的为期三个月的双盲研究,对86例患者比较了波吲洛尔和美托洛尔的降压效果。确定了不良反应的发生率,并对治疗前后的生化参数进行了跟踪。两种药物在控制血压方面同样有效。在70%的轻度和中度高血压患者中,单药使用β受体阻滞剂可使舒张压值低于95 mmHg。不良反应发生率低,药物耐受性良好。在研究的三个月内生化参数未发生变化。